NCT07078695 - A Trial of SHR-1139 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Psoriasis

Interventions

DRUG

SHR-1139 Injection

Single dose of SHR-1139 given subcutaneously (dose level 1 )

DRUG

SHR-1139 Injection

Single dose of SHR-1139 given subcutaneously (dose level 2 )

DRUG

SHR-1139 Injection

Single dose of SHR-1139 given intravenously (dose level 3)

Trial Locations (1)

RECRUITING

Linear, Perth

All Listed Sponsors

lead

Atridia Pty Ltd.

INDUSTRY